1.08
Metavia Inc (MTVA) 最新ニュース
MetaVia’s obesity drug shows promising weight loss in early trials - Investing.com
MetaVia (NASDAQ: MTVA) reports DA-1726 PK supports weekly dosing; 6.3% weight loss - Stock Titan
Is it too late to sell MetaVia Inc.2025 Institutional Moves & Fast Exit and Entry Trade Guides - newser.com
Why MetaVia Inc. stock could outperform in 2025Earnings Trend Report & Real-Time Market Sentiment Alerts - newser.com
Real time breakdown of MetaVia Inc. stock performance2025 Technical Overview & High Accuracy Trade Alerts - newser.com
How to build a dashboard for MetaVia Inc. stockMarket Sentiment Summary & Accurate Buy Signal Alerts - newser.com
What’s next for MetaVia Inc. stock price2025 Major Catalysts & Free Growth Oriented Trading Recommendations - newser.com
MetaVia Inc. stock prediction for this weekJuly 2025 Closing Moves & Scalable Portfolio Growth Ideas - newser.com
MetaVia Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
How to manage a losing position in MetaVia Inc.July 2025 Trends & AI Powered Trade Plan Recommendations - newser.com
Sector ETF performance correlation with MetaVia Inc.Trade Ideas & Daily Oversold Bounce Ideas - newser.com
How MetaVia Inc. stock reacts to bond yields2025 Trading Volume Trends & Real-Time Volume Spike Alerts - newser.com
Ranking MetaVia Inc. among high performing stocks via toolsJuly 2025 Catalysts & Low Risk Growth Stock Ideas - newser.com
Metavia Inc. Advances Obesity Treatment with New Clinical Study - TipRanks
MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting - Lelezard
MetaVia (Nasdaq: MTVA) to present vanoglipel (DA-1241) MASH poster at AASLD Nov 10 - Stock Titan
大文字化:
|
ボリューム (24 時間):